Advertisement
help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 11, No. 8, 887-894, September 2006; doi:10.1634/theoncologist.11-8-887
© 2006 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Riedel, R. F.
Right arrow Articles by Burfeind, W. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Riedel, R. F.
Right arrow Articles by Burfeind, W. R., Jr

The Community Oncologist: Duke Oncology Fellows Series

Thymoma: Benign Appearance, Malignant Potential

Richard F. Riedela,c, William R. Burfeind, Jrb,c

a Divisions of Medical Oncology and Hematology and b Division of Thoracic Surgery, Duke University Medical Center, Durham, North Carolina, USA; c The Ruth & Herman Albert Thoracic Oncology Program, Duke Comprehensive Cancer Center, Durham, North Carolina, USA

Key Words. Thymoma • Surgery • Adjuvant radiation • Chemotherapy • Paraneoplastic syndromes

Correspondence: William R. Burfeind Jr, M.D., DUMC 3305, Durham, North Carolina 27710, USA. Telephone: 919-684-8111; Fax: 919-684-8508; e-mail: william.burfeind{at}duke.edu

Thymoma is a rare tumor with a largely indolent growth pattern. It does, however, have malignant potential as a result of its ability to invade locally and metastasize regionally. Often associated with a number of immune- and nonimmune-mediated paraneoplastic syndromes, patient outcomes are directly related to stage of disease and the ability to achieve a complete surgical resection. Surgery is the mainstay of treatment, with adjuvant radiation recommended for invasive thymoma. Sensitive to both chemotherapy and radiation, durable responses are achievable in incompletely resected and inoperable patients. We present two cases of thymoma followed by a general discussion with an emphasis on treatment for both early and advanced-stage disease.




This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
S. Margaritora, A. Cesario, G. Cusumano, E. Meacci, R. D'Angelillo, S. Bonassi, G. Carnassale, V. Porziella, A. Tessitore, M. L. Vita, et al.
Thirty-Five-Year Follow-Up Analysis of Clinical and Pathologic Outcomes of Thymoma Surgery.
Ann. Thorac. Surg., January 1, 2010; 89(1): 245 - 252.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2006 by AlphaMed Press.
Advertisement